Saisheng Pharmaceutical's Miconazole Oral Patch Nomico® is officially launched commercially

Shanghai, November 8, 2021/PRNewswire/ - On November 6, 2021, Saisheng Pharmaceutical Holdings Co.

Mr.

Difficult oropharyngeal candidiasis

Oropharyngeal candidiasis is an opportunistic mucosal infectious disease mainly caused by Candida albicans infection [1]

At present, oropharyngeal candidiasis is mainly divided into four types in clinical practice, which are thrush which is more common in infants and severely ill patients, antibiotic stomatitis which is more common in adults, chronic proliferative type which is more common in patients with immune insufficiency, and common Denture stomatitis in patients who wear dentures

Special groups are easily "captured"

Although healthy people may carry Candida in the mouth, digestive tract, and vagina, for special populations, they are more susceptible to oropharyngeal candidiasis

Professor Wang Baocheng, Chief Physician of the Oncology Department of the 960th Hospital of the People’s Liberation Army (formerly the General Hospital of Jinan Military Region), said: “Because patients with malignant tumors are usually accompanied by weakened immunity, oropharyngeal candidiasis is very common in this population, especially when patients receive chemotherapy and radiotherapy.

Professor Shen Zhixiang, chief physician of the Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, also said: “Hematological malignancies such as leukemia, lymphoma, etc.

Nomico® Miconazole Patch - an innovative antifungal drug for the treatment of oropharyngeal candidiasis

Miconazole is a broad-spectrum antifungal drug that is effective against various Candida species

Nomeco® is suitable for the treatment of oropharyngeal candidiasis among adults who are receiving antibiotics or glucocorticoid therapy, HIV-infected persons, tumors and other immunodeficiency persons, and denture wearers

Mr.

About Nomic®

Nomico® is a patented oral patch of miconazole, specifically for oropharyngeal candidiasis (OPC)

About Saisheng Pharmaceutical

Saisheng Pharmaceutical Holdings Co.

For more information about Sciclone, please visit:Liu Weida, et al.

2.

3.

4.

Source: Saisheng Pharmaceutical (China) Co.
, Ltd.